SANTHERA PHARM.HD.SF 0,01 | 13.720 |
Date/Time | 06/28 / 00:00 |
Chg. / Chg.(%) | - / |
Bid | - |
Ask | - |
Open | 13.640 |
Previous Close | 13.620 |
High | 13.720 |
Low | 13.640 |
Volume [EUR] | 0.000 |
Volume [Units] | 0 |
Price fixings | 0 |
ISIN | CH0027148649 |
Security | S3F |
Exchange | Berlin |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
SIX Swiss Ex.. | 0.6250 | ![]() |
235,005 |
Cboe Europe .. | 0.62 | ![]() |
4,780 |
Turquoise | 0.62 | ![]() |
1,424 |
Cboe Europe .. | 0.63 | ![]() |
1,279 |
Lang & Schwa.. | 0.61 | ![]() |
|
London Domes.. | 0.6250 | 255 | |
Nasdaq Other.. | 1.2000 | 120 | |
München | 13.700 | 0 | |
Berlin | 13.720 | 0 | |
Frankfurt | 13.6400 | 0 | |
TradeGate | 13.76 | 0 |
News
- Santhera and ReveraGen Start Rolling NDA Submission to the FDA for Vamorolone for the Treatment of Duchenne Muscular Dystrophy
03/29/2022 / 07:00 - GlobeNewswire - Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystrophy Association Conference
03/15/2022 / 07:05 - GlobeNewswire - Santhera Completes Ordinary Capital Increase to Create Treasury Shares for Future Financing
03/15/2022 / 07:00 - GlobeNewswire - Santhera Announces Preliminary 2021 Financial Results and Increases Issued Share Capital to Create Treasury Shares for Future Financing
03/11/2022 / 07:00 - GlobeNewswire - Santhera Signs Gene Therapy Agreement with SEAL Therapeutics
02/28/2022 / 07:00 - GlobeNewswire